|
|
Line 3: |
Line 3: |
| <StructureSection load='6lt6' size='340' side='right'caption='[[6lt6]], [[Resolution|resolution]] 2.15Å' scene=''> | | <StructureSection load='6lt6' size='340' side='right'caption='[[6lt6]], [[Resolution|resolution]] 2.15Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[6lt6]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Macmu Macmu]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LT6 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6LT6 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6lt6]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Macaca_mulatta Macaca mulatta]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6LT6 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6LT6 FirstGlance]. <br> |
- | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EKG:(2R)-2,3-dihydroxypropyl+hexadecanoate'>EKG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.15Å</td></tr> |
- | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[6lah|6lah]], [[6lam|6lam]], [[6lb2|6lb2]]</td></tr>
| + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=EKG:(2R)-2,3-dihydroxypropyl+hexadecanoate'>EKG</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr> |
- | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">Mamu-B, B ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9544 MACMU]), B2M ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9544 MACMU])</td></tr>
| + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6lt6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lt6 OCA], [https://pdbe.org/6lt6 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6lt6 RCSB], [https://www.ebi.ac.uk/pdbsum/6lt6 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6lt6 ProSAT]</span></td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6lt6 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6lt6 OCA], [http://pdbe.org/6lt6 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6lt6 RCSB], [http://www.ebi.ac.uk/pdbsum/6lt6 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6lt6 ProSAT]</span></td></tr> | + | |
| </table> | | </table> |
| == Function == | | == Function == |
- | [[http://www.uniprot.org/uniprot/B2MG_MACMU B2MG_MACMU]] Component of the class I major histocompatibility complex (MHC). Involved in the presentation of peptide antigens to the immune system (By similarity). | + | [https://www.uniprot.org/uniprot/B2ZHY7_MACMU B2ZHY7_MACMU] |
| <div style="background-color:#fffaf0;"> | | <div style="background-color:#fffaf0;"> |
| == Publication Abstract from PubMed == | | == Publication Abstract from PubMed == |
Line 20: |
Line 19: |
| </div> | | </div> |
| <div class="pdbe-citations 6lt6" style="background-color:#fffaf0;"></div> | | <div class="pdbe-citations 6lt6" style="background-color:#fffaf0;"></div> |
| + | |
| + | ==See Also== |
| + | *[[Beta-2 microglobulin 3D structures|Beta-2 microglobulin 3D structures]] |
| + | *[[MHC 3D structures|MHC 3D structures]] |
| + | *[[MHC I 3D structures|MHC I 3D structures]] |
| == References == | | == References == |
| <references/> | | <references/> |
Line 25: |
Line 29: |
| </StructureSection> | | </StructureSection> |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Macmu]] | + | [[Category: Macaca mulatta]] |
- | [[Category: Morita, D]] | + | [[Category: Morita D]] |
- | [[Category: Shima, Y]] | + | [[Category: Shima Y]] |
- | [[Category: Complex]]
| + | |
- | [[Category: Immune system]]
| + | |
- | [[Category: Lysophospholipid]]
| + | |
- | [[Category: Mhc class i protein]]
| + | |
| Structural highlights
Function
B2ZHY7_MACMU
Publication Abstract from PubMed
Newly synthesized major histocompatibility complex (MHC) class I proteins are stabilized in the endoplasmic reticulum (ER) by binding 8- to 10-mer-long self-peptide antigens that are provided by transporter associated with antigen processing (TAP). These MHC class I:peptide complexes then exit the ER and reach the plasma membrane, serving to sustain the steady state MHC class I expression on the cell surface. A novel subset of MHC class I molecules that preferentially bind lipid-containing ligands rather than conventional peptides was recently identified. The primate classical MHC class I allomorphs, Mamu-B*098 and Mamu-B*05104, are capable of binding the N-myristoylated 5-mer (C14-Gly-Gly-Ala-Ile-Ser) or 4-mer (C14-Gly-Gly-Ala-Ile) lipopeptides derived from the N-myristoylated SIV Nef protein, respectively, and of activating lipopeptide antigen-specific cytotoxic T lymphocytes. We herein demonstrate that Mamu-B*098 samples lysophosphatidylethanolamine and lysophosphatidylcholine containing up to a C20 fatty acid in the ER. The X-ray crystal structures of Mamu-B*098 and Mamu-B*05104 complexed with lysophospholipids at high resolution revealed that the B and D pockets in the antigen-binding grooves of these MHC class I molecules accommodate these lipids through a mono-acyl glycerol moiety. Consistent with the capacity to bind cellular lipid ligands, these two MHC class I molecules did not require TAP function for cell-surface expression. Collectively, these results indicate that peptide- and lipopeptide-presenting MHC class I subsets use distinct sources of endogenous ligands.
Crystal structures of lysophospholipid-bound MHC class I molecules.,Shima Y, Morita D, Mizutani T, Mori N, Mikami B, Sugita M J Biol Chem. 2020 Apr 8. pii: RA119.011932. doi: 10.1074/jbc.RA119.011932. PMID:32269076[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
See Also
References
- ↑ Shima Y, Morita D, Mizutani T, Mori N, Mikami B, Sugita M. Crystal structures of lysophospholipid-bound MHC class I molecules. J Biol Chem. 2020 Apr 8. pii: RA119.011932. doi: 10.1074/jbc.RA119.011932. PMID:32269076 doi:http://dx.doi.org/10.1074/jbc.RA119.011932
|